Urine Protein Concentration with Vivaproducts Concentrators

Background

Measurement of proteins in urine is important for the diagnosis and monitoring of a variety of diseases and disorders. Normally proteins larger than 100,000 Daltons (100 kDa) such as immunoglobulins are retained in blood and much smaller molecules (<10 kDa) pass freely into the urine. Intermediate sized molecules such as albumin (~69 kDa) and free light chains (FLC) (~25 kDa) will pass into urine to varying degrees and then usually be reabsorbed by the nephron tubular system. However, proteins can be excreted in urine as the result of several conditions. Proteinuria (excess protein in urine) is associated with glomerular and tubular diseases of the nephron as well as plasma cell disorders that cause elevated protein concentrations in the blood (overflow proteinuria). These plasma cell diseases include multiple myeloma (MM) and light chain amyloidosis (AL) and are diagnosed by the presence of monoclonal FLC, also known as Bence Jones protein *(1)*.

The International Myeloma Working Group recommends that, after diagnosis of a plasma cell disorder is made, patients should be monitored by urine protein electrophoresis (UPE) and immunofixation electrophoresis (IFE). Additionally, initial screening for AL should be done with urine samples as well as serum *(2)*. IFE uses antisera to identify the monoclonal protein (*M*-protein) as an immunoglobulin (IgG, IgA, IgM, IgD or IgE) or as a FLC. The FLC can be present as 25 kDa monomers (κ or K) or as 50 kDa dimers (λ or L). Most urine IFE samples are run with antisera for IgG, IgA, IgM, κ and λ since these represent over 90% of the M-protein isotypes *(3)*.


Figure 1

IFE of Concentrated (50x) Urine Sample

Urine sample IFE showing the presence of M-protein. Antisera selected for IgG/IgA/IgM (grouped as GAM) as well as K & L and free K & L chains. Sample shows two free L chains (dark bands in middle) and one L chain bound to a heavy chain (light band on bottom).
(Photo provided by Sebia USA)

Many investigators report that 24 hour urine collection samples need to be adequately concentrated prior to UPE and IFE *(4)(5)(6)(7)*. Densitometer scans of the UPE are then used to quantitate the amount of M-protein in the urine sample *(4)(7)*. The required degree of concentration can vary according to the electrophoretic gel and the amount of protein in the sample. While many labs concentrate 50-100x, excessive concentration should be avoided since it can overload the gel *(5)*. On the other hand, insufficient concentration can lead to not diagnosing some cases with M-proteins *(8)*. The concentration factor (CF) is calculated by dividing the starting sample volume by the final volume.

Aside from UPE and IFE, capillary electrophoresis (CE) systems are also available and provide rapid, automated separations. The electropherogram from a CE system is similar to a densitometry scan. M-protein identification can be performed with CE using antisera and is referred to "immunotyping" by Sebia or "immunodisplacement" by Helena Labs.

Concentrators

Urine concentrators utilize ultrafiltration (UF) membranes which can retain proteins on the basis of their rated molecular weight cutoff (MWCO). While the proteins are filtered by the membrane, water, salts and other small molecules pass through thereby reducing the sample volume and concentrating the retained proteins. Water can be filtered through the UF membrane using centrifugal force or absorbent material behind the filter. In order to maximize recovery of M-proteins, the concentrator should have a membrane with a MWCO of 10 kDa or less.

BJP concentrators use absorbent pads to remove water from the sample without the need for a centrifuge, vacuum pump or any other equipment. The pads are on the backside of the 7.5 kDa MWCO vertical membranes, which are sealed to the plastic sample chambers. The compartments are clearly marked showing final volumes and concentration factors. Impermeable dead stop areas on the bottom of the chambers prevent the sample from concentrating to less than ~50 µl. Samples can be easily introduced and withdrawn with convenient plastic disposable pipettes. BJP concentrators are available with sample volumes of 5 ml, 10 ml and 20 ml (with optional expansion reservoirs). They are also offered as individual test units or as blocks with 8 sample compartments. A sample of 5 ml volume can be concentrated 50x in 40-50 minutes depending on the initial total protein level.

Vivaspin® centrifugal concentrators are designed to be used with swinging bucket or fixed angle rotors. They use a patented (US 5,647,990) vertical membrane design with thin channel support to provide high speed filtration. For urine concentration, the 10 kDa MWCO is recommended for optimal recovery. As with the BJP, the Vivaspins have clearly marked volumes and dead stop compartments to prevent samples from concentrating to dryness. Vivaspins are available for a variety of sample volumes ranging from 0.5 ml to 20 ml. Urine samples of 4 ml may be concentrated 50x in about 15-20 minutes depending on the initial total protein.

Selection between Vivaspin and BJP concentrators will depend on several factors. Reference laboratories that process many samples generally prefer the faster speeds of the Vivaspins. Most labs use Vivaspin 4 devices for UPE and IFE while others, such as the Mayo Clinic, report a preference for the larger Vivaspin 20 *(6)*. BJP concentrators are usually selected by labs that don't have the proper centrifuge. Others like that the BJP sample can be viewed during the concentration process and removed when the desired final volume is reached. On the other hand, Vivaspins can yield higher concentration factors (up to 200x) since their dead stop volumes are typically less than the 50 µl of the BJP devices.

Procedures

Samples for UPE or IFE are typically collected from 24 hour urine patient specimens. First the initial total protein (TP) should be measured using colorimetric dye binding or a similar method. Then the urine should be treated to remove any sediment which could interfere with the electrophoresis results *(9)*. Such sediment can also slow down filtration rates during concentration and even totally obstruct the membrane. The sample can be clarified by use of a 10-20 µm disposable filter or by centrifuging the sample for about 5 minutes at 1000-2000 g.

As mentioned previously, the sample must be concentrated enough to provide visible bands after UPE and IFE yet not so much that the gel is overloaded. Laboratories will normally use the initial TP to determine the desired CF. The CF calculation is dependent on the minimum TP recommended for the gel being used. Most samples should be concentrated to at least 1-2 G/dL for UPE and slightly less for IFE but these numbers should be confirmed with the gel supplier. Since some labs require IFE volumes of up to 100 µl of concentrated urine (instead of about 20 µl for UPE), this final volume must be considered when calculating the desired CF.

After determining the target CF, most labs will first fill the sample reservoir to its rated capacity and stop the concentration process at the appropriate final volume. This is much simpler with a BJP since the concentrate volume is visible at all times. With a Vivaspin, the centrifugation time is adjusted to yield the correct final volume but this can be a trial and error process. If a sample is concentrated too much, filtrate or purified water/buffer can be added back to reconstitute the sample to the desired volume. Other labs will reduce the starting volume in order to reduce the final CF. This method has been used for Vivaspins and has the added benefit of reducing the centrifugation time since less sample has to be filtered.

Laboratories will usually generate a chart showing the target CF as a function of the starting TP concentration. Examples of charts are shown in Tables 1 and 2. These tables were produced using a calculator app that is available at www.vivaproducts.com/calculator.html. The app requires inputs for: (1) the type of concentrator, (2) choice of UPE or IFE, (3) the final desired TP for electrophoresis, and (4) the choice of constant or variable sample volume. Note that the app produces suggested CF values and increased concentration may be needed to detect faint M-protein bands in some cases. Following concentration, M-protein peaks found on the gel should be scanned and fractionated on a densitometer. Then the amount of M-protein in the 24 hour urine sample may be calculated by multiplying the amount of that fraction in the electropherogram by the starting urinary TP concentration *(4)(7)*.

Initial TP Conc. (mg/dL)	Sample Volume (mL)	Conc. Volume (µL)	Conc. Factor	Final TP Conc. (G/dL)
< 20	10	50	200	< 4.0
20 – 40	10	100	100	2.0 – 4.0
41 – 80	10	200	50	2.1 – 4.0
81 – 200	10	400	25	2.0 – 5.0
201 – 400	10	1000	10	2.0 – 4.0
> 400	10	2000	5	> 2.0

Table 1

Urine Concentration Chart

Values for UPE using a BJP-10 with Constant Sample Volume and desired Final TP of 2.0 G/dL

Initial TP Conc. (mg/dL)	Sample Volume (mL)	Conc. Volume (µL)	Conc. Factor	Final TP Conc. (G/dL)
< 25	8	100	80	< 2.0
25 – 50	4	100	40	1.0 – 2.0
51 – 100	2	100	20	1.0 – 2.0
101 – 250	1	100	10	1.0 – 2.5
> 250	0.4	100	4	> 1.0

Table 2

Urine Concentration Chart

Values for IFE using a Vivaspin 4 with Variable Sample Volume and desired Final TP of 1.0 G/dL

NOTE: **Two Vivaspin 4 devices are used to provide enough sample for IFE. Need 8 mL total sample concentrated to 50 µL in each Vivaspin.**

Capillary electrophoresis systems require urine samples to be prepared by ultrafiltration devices prior to analysis. Samples are first diluted with water and concentrated to remove salts. Then buffer is added and samples are centrifuged again to exchange the buffer. Sebia and Helena Labs both recommend the use of Vivaspin 20 devices to prepare urine samples for their capillary systems *(10)(11)*.

CAP Validation

Concentration procedures should be validated on a regular basis to comply with quality inspections conducted by the College of American Pathologists (CAP). One popular method involves measuring TP recovery after concentrating urine samples according these steps:

(1) Prepare the urine as discussed previously and determine the initial TP (TP1).
(2) Fill the concentrator with the sample volume (V1) and perform the concentration.
(3) Measure the final volume (V2) <u>accurately</u> and then measure the final TP (TP2).
(4) Calculate the CF according to the equation CF = V1 / V2.
(5) Calculate the recovery (R) where R = 1000 x TP2 / (CF x TP1). The 1000 factor is to convert TP2 from G/dL to mg/dL. Multiply by 100 for %.

The sample results can be entered into a spreadsheet to calculate the average TP recovery (see example in Table 3). Labs should define their own quality criteria but 70 – 80% is usually acceptable. This table may be downloaded at http://www.vivaproducts.com/downloads/cap-recovery-table.xls.

Note that using TP is not completely accurate as a method to check recovery of M-proteins. TP values can include small proteins and polypeptides that are not clinically significant when diagnosing M-proteins. These small molecules can pass through the membrane and not be concentrated so they reduce the TP recovery %. Samples with higher TP values usually show higher recoveries since the small molecules represent a lesser percentage of the total.

Sample Number	TP1 – Starting Conc. (mg/dL)	V1 – Sample Volume (mL)	V2 – Conc. Volume (µL)	CF	TP2 – Final Conc. (G/dL)	Recovery R=1000 x TP2/(CF x TP1)
1	30	4	50	80	2.0	83%
2	120	4	200	20	2.2	92%
3	18	4	20	200	2.9	81%
4	60	4	100	40	2.1	88%
Average						**86%**

Table 3

Urine Concentration   CAP Validation Chart

Values for TP readings using Vivaspin 4 devices with various patient samples.

Another method for validation is to perform a series of concentration tests on split samples. For example, the urine could be split into 5 samples of 5 ml each. Four of these could be concentrated to the following CF values: (1) 10x, (2) 25x, (3) 50x and (4) 100x. A UPE would be performed for each of these along with the unconcentrated (neat) sample. The bands of the UPE should become darker as the CF increases. Note that this is not a quantitative test but is used by some labs (see Figure 2). For current suggested CAP validation procedures, visit our website at https://www.vivaproducts.com/downloads/lab-procedure-performing-the-test.pdf.

Figure 2
CAP Validation by Serial Concentration of Urine Sample

Patterns for UPE for a single urine sample with starting TP of 30 – 100 mg/dL (measured by Multistix 10).
Albumin bands show on bottom & M-protein show on top (see arrows).
Sample is split and concentrated to increasing CF as shown on bottom.
Note that the Neat sample does not show a visible M-protein band.

IVD Devices

All the BJP and some Vivaspin concentrators (see below Table 4) are intended for *in vitro* diagnostic (IVD) use specifically for concentration of urine, cerebrospinal fluid and other bodily fluids before analysis by electrophoresis or other methods. While other Vivaspin concentrators are used for general research purposes, the IVD versions are labeled accordingly (IVD). Both the BJP and IVD Vivaspin concentrators are single use devices and are registered as Class 1 medical devices with the US FDA. These products have an FDA Product Classification of Clinical Sample Concentrator (Code JJH) and fall under Regulation Number 862.2310 which is 510(K) Exempt.

Product	Vivaspin 4	Vivaspin 4 Turbo	Vivaspin 6	Vivaspin 15 Turbo	Vivaspin 20
12/PK				VS15T01IVD	VS2001IVD
25/PK	VS0403	VS04T01IVD	VS0601IVD		
48/PK				VS15T02IVD	VS2002IVD
100/PK	VS0404	VS04T02IVD	VS0602IVD		
500/PK	VS0405		VS0603		

Table 4
IVD Vivaspin Concentrator Product Numbers

References

1. Winter, W.E. (2012). Urine Protein Electrophoresis. In: Harris, N.S. & Winter, W.E. (editors). *Multiple Myeloma and Related Serum Protein Disorders: An Electrophoretic Guide*. 1st ed. (pp. 83-115). New York: Demos Medical Publishing.

2. International Myeloma Working Group (2009). International Myeloma Working Group Guidelines for Serum-Free Light Chain Analysis in Multiple Myeloma and Related Disorders. *Leukemia*, 23, 215-224.

3. Keren, D.F. (2012). *Protein Electrophoresis in Clinical Diagnosis*. (pp. 105-154). Chicago: ASCP Press.

4. International Myeloma Workshop Consensus Panel 3 (2011). Consensus Recommendations for Standard Investigative Workup: Report of the International Myeloma Workshop Consensus Panel 3. *Blood*, 117, 4701-4705.

5. Keren, D.F. (2012). *Protein Electrophoresis in Clinical Diagnosis*. (pp. 155-178). Chicago: ASCP Press.

6. Katzmann, J., Kyle, R.A., Lust, J., Snyder, M. & Dispenzieri, A. (2012). Immunoglobulins and Laboratory Recognition of Monoclonal Proteins. In: Wiernik, P.H., Goldman, J.M., Dutcher, J.P. & Kyle, R.A. (editors). *Neoplastic Diseases of the Blood*. 5th ed. (pp. 565-588). New York: Springer.

7. Kyle, R.A. (1999). Sequence of Testing for Monoclonal Gammopathies: Serum and Urine Assays. *Arch Pathol Lab Med*, 123(2), 114-118.

8. Kaplan, I.V. & Levinson, S.S. (1999). Misleading Urinary Protein Pattern in a Patient with Hypogammaglobulinemia: Effects of Mechanical Concentration of Urine. *Clin Chem,* 45(3), 417-419.

9. Keren, D.F., Gulbranson, R. & Ebrom, S.J. (2004). False-Negative Urine Protein Electrophoresis by Semi-Automated Gel Electrophoresis. *Clin Chem,* 50(5), 933-934.

10. Sebia (2012). Capillarys Urine Assay Using 20mL Vivaspin® Tubes or Equivalent. *Sebia Quick Reference Guide* CPY 41|Rev. 07.12.2012.

11. Helena Labs (2013). Quick Guide for V8 CE: Urine Prep with VS2002 Centrifugal Concentrators*. Helena Labs Quick Guide.
    (* For Investigational Use Only: The performance characteristics of this product have not been established.)